Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.48
MDT's Cash to Debt is ranked lower than
75% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDT: 0.48 )
Ranked among companies with meaningful Cash to Debt only.
MDT' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.75 Max: 9.58
Current: 0.48
0.15
9.58
Equity to Asset 0.50
MDT's Equity to Asset is ranked lower than
72% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDT: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
MDT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.60 Max: 0.82
Current: 0.5
0.37
0.82
Interest Coverage 4.60
MDT's Interest Coverage is ranked lower than
93% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. MDT: 4.60 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 5.65  Med: 11.33 Max: 28.8
Current: 4.6
5.65
28.8
F-Score: 5
Z-Score: 2.82
M-Score: -1.93
WACC vs ROIC
9.64%
5.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.87
MDT's Operating margin (%) is ranked higher than
89% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. MDT: 19.87 )
Ranked among companies with meaningful Operating margin (%) only.
MDT' s Operating margin (%) Range Over the Past 10 Years
Min: 16.71  Med: 24.36 Max: 30.17
Current: 19.87
16.71
30.17
Net-margin (%) 12.42
MDT's Net-margin (%) is ranked higher than
81% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MDT: 12.42 )
Ranked among companies with meaningful Net-margin (%) only.
MDT' s Net-margin (%) Range Over the Past 10 Years
Min: 13.2  Med: 19.78 Max: 22.78
Current: 12.42
13.2
22.78
ROE (%) 5.85
MDT's ROE (%) is ranked higher than
59% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDT: 5.85 )
Ranked among companies with meaningful ROE (%) only.
MDT' s ROE (%) Range Over the Past 10 Years
Min: 7.36  Med: 20.03 Max: 27.52
Current: 5.85
7.36
27.52
ROA (%) 2.82
MDT's ROA (%) is ranked higher than
60% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. MDT: 2.82 )
Ranked among companies with meaningful ROA (%) only.
MDT' s ROA (%) Range Over the Past 10 Years
Min: 3.7  Med: 10.64 Max: 14.3
Current: 2.82
3.7
14.3
ROC (Joel Greenblatt) (%) 47.92
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. MDT: 47.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 51.21  Med: 68.07 Max: 91.32
Current: 47.92
51.21
91.32
Revenue Growth (3Y)(%) 6.20
MDT's Revenue Growth (3Y)(%) is ranked higher than
60% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. MDT: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.2  Med: 12.80 Max: 17.9
Current: 6.2
4.2
17.9
EBITDA Growth (3Y)(%) 0.50
MDT's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. MDT: 0.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.5  Med: 9.90 Max: 45.4
Current: 0.5
-15.5
45.4
EPS Growth (3Y)(%) -9.20
MDT's EPS Growth (3Y)(%) is ranked lower than
67% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. MDT: -9.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MDT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.2  Med: 13.70 Max: 27.7
Current: -9.2
-9.2
27.7
» MDT's 10-Y Financials

Financials (Next Earnings Date: 2016-03-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MDT Guru Trades in Q1 2015

First Pacific Advisors 2,147,307 sh (New)
Ronald Muhlenkamp 173,653 sh (New)
Caxton Associates 30,000 sh (New)
Louis Moore Bacon 25,233 sh (New)
Jeremy Grantham 7,402,676 sh (+182862.83%)
Mario Gabelli 66,282 sh (+562.82%)
Ray Dalio 172,832 sh (+371.81%)
Pioneer Investments 2,760,285 sh (+250.16%)
Paul Tudor Jones 11,800 sh (+210.53%)
Joel Greenblatt 37,793 sh (+92.74%)
HOTCHKIS & WILEY 5,753,016 sh (+79.34%)
Vanguard Health Care Fund 18,885,933 sh (+44.75%)
John Keeley 40,512 sh (+22.10%)
Ken Fisher 6,717 sh (+8.46%)
Ruane Cunniff 4,880 sh (+3.83%)
John Buckingham 19,377 sh (+1.71%)
John Hussman 200,000 sh (unchged)
Bill Nygren 4,690,000 sh (unchged)
Robert Olstein 134,000 sh (unchged)
Dodge & Cox 8,696,577 sh (-1.37%)
James Barrow 31,889,163 sh (-2.30%)
Diamond Hill Capital 3,566,702 sh (-3.04%)
Jeff Auxier 140,083 sh (-3.98%)
Mairs and Power 3,254,448 sh (-4.18%)
PRIMECAP Management 17,545,221 sh (-5.56%)
First Eagle Investment 937,172 sh (-24.20%)
Steven Cohen 136,200 sh (-79.33%)
Steven Romick 2,020,579 sh (-183.29%)
» More
Q2 2015

MDT Guru Trades in Q2 2015

John Burbank 2,694 sh (New)
Steven Cohen 596,400 sh (+337.89%)
John Buckingham 20,357 sh (+5.06%)
Jeremy Grantham 7,545,614 sh (+1.93%)
First Pacific Advisors 2,169,396 sh (+1.03%)
Ronald Muhlenkamp 173,750 sh (+0.06%)
John Keeley 40,520 sh (+0.02%)
Vanguard Health Care Fund 18,885,933 sh (unchged)
Steven Romick 2,020,579 sh (unchged)
Robert Olstein 134,000 sh (unchged)
Ruane Cunniff 4,880 sh (unchged)
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Jeff Auxier 139,583 sh (-0.36%)
Diamond Hill Capital 3,550,528 sh (-0.45%)
Mario Gabelli 65,949 sh (-0.50%)
James Barrow 31,616,685 sh (-0.85%)
Mairs and Power 3,213,444 sh (-1.26%)
HOTCHKIS & WILEY 5,619,508 sh (-2.32%)
Ken Fisher 6,445 sh (-4.05%)
PRIMECAP Management 16,396,096 sh (-6.55%)
Dodge & Cox 8,011,783 sh (-7.87%)
Bill Nygren 4,190,000 sh (-10.66%)
John Hussman 175,000 sh (-12.50%)
Pioneer Investments 2,376,902 sh (-13.89%)
Ray Dalio 85,132 sh (-50.74%)
First Eagle Investment 12,735 sh (-98.64%)
» More
Q3 2015

MDT Guru Trades in Q3 2015

Jim Simons 531,441 sh (New)
Joel Greenblatt 10,247 sh (New)
Paul Tudor Jones 151,700 sh (New)
Manning & Napier Advisors, Inc 2,671,920 sh (New)
First Eagle Investment 17,735 sh (+39.26%)
Vanguard Health Care Fund 20,081,233 sh (+6.33%)
Ruane Cunniff 5,075 sh (+4.00%)
John Buckingham 21,140 sh (+3.85%)
Pioneer Investments 2,451,935 sh (+3.16%)
Bill Nygren 4,190,000 sh (unchged)
Robert Olstein 134,000 sh (unchged)
John Keeley 40,520 sh (unchged)
John Hussman 175,000 sh (unchged)
First Pacific Advisors Sold Out
John Burbank Sold Out
Steven Romick Sold Out
Jeff Auxier 139,473 sh (-0.08%)
Ronald Muhlenkamp 173,364 sh (-0.22%)
Mairs and Power 3,171,922 sh (-1.29%)
James Barrow 30,967,127 sh (-2.05%)
Diamond Hill Capital 3,466,464 sh (-2.37%)
Jeremy Grantham 7,197,272 sh (-4.62%)
HOTCHKIS & WILEY 5,290,450 sh (-5.86%)
PRIMECAP Management 15,260,876 sh (-6.92%)
Ken Fisher 5,939 sh (-7.85%)
Dodge & Cox 6,971,380 sh (-12.99%)
Steven Cohen 500,900 sh (-16.01%)
Mario Gabelli 46,079 sh (-30.13%)
Ray Dalio 57,186 sh (-32.83%)
» More
Q4 2015

MDT Guru Trades in Q4 2015

First Eagle Investment 1,940,036 sh (+10839.02%)
Pioneer Investments 4,269,571 sh (+74.13%)
John Buckingham 22,788 sh (+7.80%)
Vanguard Health Care Fund 20,081,233 sh (unchged)
John Hussman 175,000 sh (unchged)
Jim Simons Sold Out
Ronald Muhlenkamp Sold Out
Jeff Auxier 139,273 sh (-0.14%)
PRIMECAP Management 15,187,651 sh (-0.48%)
Ken Fisher 5,905 sh (-0.57%)
Diamond Hill Capital 3,436,197 sh (-0.87%)
Dodge & Cox 6,867,935 sh (-1.48%)
James Barrow 30,282,119 sh (-2.21%)
Ray Dalio 53,186 sh (-6.99%)
Mario Gabelli 40,111 sh (-12.95%)
Robert Olstein 108,000 sh (-19.40%)
Jeremy Grantham 4,545,540 sh (-36.84%)
John Keeley 25,281 sh (-37.61%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic PLC

Bill Frels Comments on Medtronic Inc - Oct 20, 2014

Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone.

As of September 30, 2014, the market value of the Growth Fund’s holding in Medtronic was $24 per share greater than its cost basis. We estimate that our typical shareholder, that holds the Growth Fund in a taxable amount, will experience about a $6.00 per share tax liability. We do not offer tax advice; each shareholder should consult a tax advisor about his/her particular circumstance. Providing that there are no significant changes, our current thinking leads us to believe that voting for the merger is in our shareholders’ best interest. We will keep you posted as the voting date is finalized or if we learn of any other developments regarding the merger plans.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jul 31, 2014

Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share.

From Bill Frels (Trades, Portfolio)’ Mairs & Power Growth Fund Second Quarter 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jun 25, 2014

Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue.



From Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Medtronic PLC

Hotchkis & Wiley Adds to Banking, Insurance Stakes
In its 35-year existence, value investor HOTCHKIS & WILEY has built its reputation on identifying undervalued companies that have great growth potential. But in the first quarter, most of its emphasis was on well-established companies, especially those in banking and insurance. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.46
MDT's P/E(ttm) is ranked lower than
68% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. MDT: 38.46 )
Ranked among companies with meaningful P/E(ttm) only.
MDT' s P/E(ttm) Range Over the Past 10 Years
Min: 10.14  Med: 20.43 Max: 43.51
Current: 38.46
10.14
43.51
Forward P/E 15.11
MDT's Forward P/E is ranked higher than
77% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. MDT: 15.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 38.46
MDT's PE(NRI) is ranked lower than
71% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 27.40 vs. MDT: 38.46 )
Ranked among companies with meaningful PE(NRI) only.
MDT' s PE(NRI) Range Over the Past 10 Years
Min: 10.13  Med: 20.46 Max: 43.51
Current: 38.46
10.13
43.51
P/B 1.95
MDT's P/B is ranked higher than
63% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MDT: 1.95 )
Ranked among companies with meaningful P/B only.
MDT' s P/B Range Over the Past 10 Years
Min: 1.78  Med: 3.06 Max: 6.52
Current: 1.95
1.78
6.52
P/S 3.75
MDT's P/S is ranked lower than
75% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. MDT: 3.75 )
Ranked among companies with meaningful P/S only.
MDT' s P/S Range Over the Past 10 Years
Min: 2.61  Med: 4.82 Max: 9.13
Current: 3.75
2.61
9.13
PFCF 18.49
MDT's PFCF is ranked higher than
85% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 34.47 vs. MDT: 18.49 )
Ranked among companies with meaningful PFCF only.
MDT' s PFCF Range Over the Past 10 Years
Min: 9.2  Med: 14.45 Max: 70.14
Current: 18.49
9.2
70.14
POCF 16.07
MDT's POCF is ranked higher than
73% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 19.47 vs. MDT: 16.07 )
Ranked among companies with meaningful POCF only.
MDT' s POCF Range Over the Past 10 Years
Min: 8.13  Med: 12.63 Max: 32.39
Current: 16.07
8.13
32.39
EV-to-EBIT 37.58
MDT's EV-to-EBIT is ranked lower than
74% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. MDT: 37.58 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.6  Med: 18.70 Max: 37.91
Current: 37.58
11.6
37.91
EV-to-EBITDA 26.88
MDT's EV-to-EBITDA is ranked lower than
74% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. MDT: 26.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.8  Med: 15.60 Max: 30
Current: 26.88
9.8
30
PEG 19.50
MDT's PEG is ranked lower than
87% of the 68 Companies
in the Global Medical Devices industry.

( Industry Median: 3.39 vs. MDT: 19.50 )
Ranked among companies with meaningful PEG only.
MDT' s PEG Range Over the Past 10 Years
Min: 1.15  Med: 1.86 Max: 17.64
Current: 19.5
1.15
17.64
Shiller P/E 26.17
MDT's Shiller P/E is ranked higher than
68% of the 72 Companies
in the Global Medical Devices industry.

( Industry Median: 31.42 vs. MDT: 26.17 )
Ranked among companies with meaningful Shiller P/E only.
MDT' s Shiller P/E Range Over the Past 10 Years
Min: 14.42  Med: 22.24 Max: 56.65
Current: 26.17
14.42
56.65
Current Ratio 3.53
MDT's Current Ratio is ranked higher than
63% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. MDT: 3.53 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.44 Max: 6.8
Current: 3.53
0.88
6.8
Quick Ratio 3.10
MDT's Quick Ratio is ranked higher than
67% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MDT: 3.10 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.94 Max: 6.46
Current: 3.1
0.66
6.46
Days Inventory 178.90
MDT's Days Inventory is ranked lower than
64% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. MDT: 178.90 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 178.9
132.14
164.01
Days Sales Outstanding 98.72
MDT's Days Sales Outstanding is ranked lower than
71% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. MDT: 98.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 76.96  Med: 81.90 Max: 92.09
Current: 98.72
76.96
92.09
Days Payable 91.60
MDT's Days Payable is ranked higher than
68% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. MDT: 91.60 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 32.49  Med: 45.89 Max: 93.14
Current: 91.6
32.49
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.97
MDT's Dividend Yield is ranked higher than
63% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.72 vs. MDT: 1.97 )
Ranked among companies with meaningful Dividend Yield only.
MDT' s Dividend Yield Range Over the Past 10 Years
Min: 0.61  Med: 1.84 Max: 2.93
Current: 1.97
0.61
2.93
Dividend Payout 0.78
MDT's Dividend Payout is ranked lower than
84% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 0.34 vs. MDT: 0.78 )
Ranked among companies with meaningful Dividend Payout only.
MDT' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.24 Max: 2.04
Current: 0.78
0.14
2.04
Dividend Growth (3y) 7.90
MDT's Dividend Growth (3y) is ranked higher than
61% of the 64 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. MDT: 7.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MDT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7.6  Med: 15.50 Max: 26
Current: 7.9
7.6
26
Forward Dividend Yield 2.07
MDT's Forward Dividend Yield is ranked higher than
62% of the 176 Companies
in the Global Medical Devices industry.

( Industry Median: 1.76 vs. MDT: 2.07 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.91
MDT's Yield on cost (5-Year) is ranked higher than
72% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. MDT: 2.91 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MDT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.9  Med: 2.72 Max: 4.33
Current: 2.91
0.9
4.33
3-Year Average Share Buyback Ratio -1.50
MDT's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: -4.30 vs. MDT: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.3  Med: 0.30 Max: 2.6
Current: -1.5
-8.3
2.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.30
MDT's Price/Projected FCF is ranked higher than
76% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. MDT: 1.30 )
Ranked among companies with meaningful Price/Projected FCF only.
MDT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.77  Med: 1.51 Max: 6.95
Current: 1.3
0.77
6.95
Price/DCF (Earnings Based) 3.39
MDT's Price/DCF (Earnings Based) is ranked lower than
67% of the 43 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 3.39 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.06
MDT's Price/Median PS Value is ranked lower than
57% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MDT: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
MDT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.66  Med: 1.53 Max: 3.57
Current: 1.06
0.66
3.57
Price/Peter Lynch Fair Value 7.61
MDT's Price/Peter Lynch Fair Value is ranked lower than
90% of the 73 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. MDT: 7.61 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MDT' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.25  Med: 2.28 Max: 5.77
Current: 7.61
1.25
5.77
Earnings Yield (Greenblatt) (%) 2.64
MDT's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. MDT: 2.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.62  Med: 5.40 Max: 8.6
Current: 2.64
2.62
8.6
Forward Rate of Return (Yacktman) (%) 10.16
MDT's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 5.28 vs. MDT: 10.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.7  Med: 15.10 Max: 22.3
Current: 10.16
6.7
22.3

More Statistics

Revenue(Mil) $25954
EPS $ 1.64
Beta1.21
Short Percentage of Float1.05%
52-Week Range $55.54 - 79.50
Shares Outstanding(Mil)1806.16

Analyst Estimate

Apr16 Apr17 Apr18
Revenue(Mil) 28,163 29,418 31,670
EPS($) 4.35 4.86 5.33
EPS without NRI($) 4.35 4.86 5.33

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:MDT.Argentina, 2M6.Germany, MDT N.Mexico, MDT.Switzerland, 0QYG.UK,
Medtronic PLC was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in four operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Minimally Invasive Therapies Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Minimally Invasive Therapies Group is composed of the Surgical Solutions and Patient Monitoring & Recovery divisions. With a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications, the group looks to enhance patient outcomes through minimally invasive solutions. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of ch
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Researching United Technologies: Here’s How I Do It Feb 01 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
A Recession-Resistant Dividend Aristocrat With 10% Dividend Growth Jan 05 2016 
Despite Slowing ACA Tailwind, Medtronic Offers Strong Dividend Dec 15 2015 
Medtronic Continues to Report Solid Numbers Dec 04 2015 
Medtronic: Dividend Aristocrats Part 27 Nov 20 2015 
Several Gurus Take New Stakes in IBM Nov 18 2015 
Retired Investors: Apply a Value Investing Strategy to Earn More Income, Higher Returns Nov 06 2015 
Steven Romick Sells CVS, Buys United Technologies Oct 27 2015 
In Today’s Overheated Market Control Risk in Your Retirement Portfolios with Sound Valuation Aug 20 2015 

More From Other Websites
How Medtronic Makes Money (MDT) Feb 13 2016
[$$] Monitor implant approved for UK diabetics Feb 12 2016
NICE Recommends Medtronic Integrated Sensor-Augmented Insulin Pump As the Only Therapy System to... Feb 12 2016
MDT’s Earnings Are Expected to Continue to Grow in Fiscal 3Q16 Feb 11 2016
Edwards Battles For Top Spot in Heart Valve Market Feb 10 2016
First Patient Treated with Medtronic Valiant TAAA Stent Graft System in Thoracoabdominal Aortic... Feb 09 2016
6 Medical Device Stocks to Treat the Bear Market Blues Feb 08 2016
Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes Feb 05 2016
Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization... Feb 05 2016
5 Big Stocks to Trade for Gains in This Market Feb 04 2016
7 Cash-Rich Stocks to Buy Now Feb 04 2016
Medtronic Plc breached its 50 day moving average in a Bullish Manner : February 2, 2016 Feb 02 2016
Analysts Expect MDT’s Fiscal 3Q16 Revenues to be $6.9 Million Feb 01 2016
Latest Consensus Recommendation for Medtronic: Strong “Buy” Feb 01 2016
Health-Care Costs Continue Driving Deals for Med-Tech Companies Feb 01 2016
Medtronic Presents Innovation Village – The First-Of-Its-Kind Initiative – At The 2nd Medical... Feb 01 2016
Medtronic Adds New Resolute Onyx(TM) Drug-Eluting Stent Sizes and Expands Indications Feb 01 2016
Medtronic Adds New Resolute Onyx(TM) Drug-Eluting Stent Sizes and Expands Indications Feb 01 2016
Medtronic Adds Life-Extending Dialysis Portfolio to Recently Formed Renal Care Solutions Business... Feb 01 2016
Medtronic Adds Life-Extending Dialysis Portfolio to Recently Formed Renal Care Solutions Business... Feb 01 2016
Medtronic to Present Data on Micra® Transcatheter Pacing System at Upcoming FDA Advisory Committee... Jan 29 2016
Medtronic to Present Data on Micra® Transcatheter Pacing System at Upcoming FDA Advisory Committee... Jan 29 2016
How Did Michael Castor’s Picks Play Out in Q4? Jan 27 2016
Medical Appliances & Equipment Stocks Technical Report -- Boston Scientific, Abbott Laboratories,... Jan 27 2016
Big Pharma's bet on Big Data creates opportunities and risks Jan 26 2016
From Pepsi to Target: Bet on these leaders Jan 25 2016
Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool(TM) RF Ablation System Jan 13 2016
Medtronic narrows fiscal 2016 adjusted earnings forecast Jan 11 2016
Medtronic Updates Capital Allocation Plans and Fiscal 2016 EPS Guidance Jan 11 2016
Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage... Jan 11 2016
Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement Jan 11 2016
The latest in gadgets: Making apps and robots that think Jan 06 2016
Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference Dec 17 2015
The Medtronic Bakken Invitation Award Honors 12 Patients from Around the World for Giving Back Dec 14 2015
Medtronic Announces New High-Tech Facility in Galway; Building on Global Synergies Dec 14 2015
Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2016 Dec 11 2015
Medtronic Announces FDA Approval of Infuse® Bone Graft for Three New Spine Surgery Indications Dec 11 2015
Medtronic and Samsung Expand Alliance to Develop Connected Health Solutions for Neuromodulation... Dec 11 2015
Medtronic Announces FDA Approval for the Only Full-Body MR Conditional Deep Brain Stimulation... Dec 09 2015
University of Washington to Lead U.S. Expansion of Medtronic's HeartRescue Project Dec 08 2015
Medtronic tops 2Q profit forecasts Dec 03 2015
Medtronic Reports Second Quarter Financial Results Dec 03 2015
Medtronic Expands Access to Type 2 Diabetes Products with Selection of Henry Schein as Exclusive... Dec 02 2015
Medtronic Expands Access to Type 2 Diabetes Products with Selection of Henry Schein as Exclusive... Dec 02 2015
Medtronic Enhances Utility of Professional Continuous Glucose Monitor (CGM) by Launching Pattern... Nov 30 2015
Politicians slam tax-avoiding Pfizer-Allergan mega-deal Nov 23 2015
Promise seen for wireless pacemakers placed without surgery Nov 09 2015
EU drugs agency recommends suspension of Medtronic implant Oct 23 2015
Medtronic gets approval for MRI-safe heart implant Sep 14 2015
Medtronic to spend $458M on heart valve developer Aug 25 2015
A first: New guidelines back device for treating strokes Jun 29 2015
Medtronic boosts stock buyback, raises dividend, makes deals Jun 19 2015
Medtronic beats Street 4Q forecasts Jun 02 2015
Siemens, regulator deny China bribery report May 05 2015
FDA: Medtronic must stop most sales of Synchromed drug pumps Apr 27 2015
FDA moves to halt Medtronic's production of drug pump Apr 27 2015
TechBits: Analyzing medical data, breaking smartphones Apr 15 2015
IBM launches new health unit, teams up with Apple, J&J, Medtronic Apr 13 2015
IBM launches new health unit, teams up with Apple, J&J, Medtronic Apr 13 2015
Medical device maker settles lawsuit for $4.4 million Apr 03 2015
Medtronic to pay $4.41 million in settlement -U.S. Justice department Apr 02 2015
Medtronic to pay $4.41 million in settlement -U.S. Justice department Apr 02 2015
Medtronic tops Street 3Q forecasts Feb 17 2015
MEDIA-Tax inversion rules could lead U.S. drugmakers selling to overseas buyers : Ackman - Bloomberg Feb 12 2015
Medtronic shareholders OK $48 billion Covidien acquisition Jan 06 2015
TREASURIES-Prices sag as Wall St rallies, corporate debt deals drag Dec 02 2014
TREASURIES-Prices stung by corporate deals, 30-year yield tops 3 pct Dec 02 2014
FTC approves Medtronic acquisition of Covidien Nov 26 2014
Medtronic gets U.S. antitrust OK to buy Covidien with divestiture Nov 26 2014
Medtronic profit meets expectations; Covidien deal on track Nov 18 2014
Medtronic offers EU concessions in $43 bln Covidien deal Nov 11 2014
Medtronic offers EU concessions in $43 bln Covidien deal Nov 11 2014
EU mergers and takeovers (Nov 10) Nov 10 2014
EU mergers and takeovers (Oct 27) Oct 27 2014
Medtronic seeks EU approval for $43 bln Covidien deal Oct 13 2014
Becton Dickinson to buy CareFusion for $12 bln in cash, stock Oct 05 2014
Medtronic develops new app for monitoring glucose levels Oct 05 2014
Becton Dickinson to buy CareFusion for $12 bln in cash, stock Oct 05 2014
BUZZ-U.S. Stocks on the Move-Herbalife, net Element, Mobileye, On Track Sep 23 2014
Global medical devices market sees start-ups leading innovation and catching the attention of... Sep 16 2014
Top U.S. Senate Democrats unveil earnings stripping plan Sep 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK